Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer

NEW YORK, April 3, 2018

Bridge Medicines, a pioneering drug discovery company focused on advancing promising early technologies from concept to clinic, announced today the appointment of Louis M. Renzetti, Ph.D., as Chief Scientific Officer (CSO).